Directive transparence : information réglementée

Paris (France), October 22, 2018, 6.00pm - BIOPHYTIS (Euronext Growth Paris:
ALBPS), a biotechnology company specializing in the development of drug
candidates to fight age-related degenerative diseases, announces the
publication of its interim financial report and communicates the perspective on
its activity until year-end.

Stanislas Veillet, CEO of BIOPHYTIS, stated: "In the first half of 2018, key
steps in the clinical programs of our drug candidate Sarconeos were completed,
with the opening of the first clinical centers of the phase 2b study SARA-INT
in Sarcopenia, and the Orphan Drug Designation for Duchenne Muscular Dystrophy.
The Company which had EUR14 million of cash on June 30thand has signed a EUR10
million loan with Kreos Capital in September, has the adequate financial
resources to conduct SARA-INT and obtain the regulatory approvals for the MYODA
clinical program in DMD."

The financial report can be downloaded at :
http://www.biophytis.com/en/action/document/

Key highlights of 2018's first semester

In the first semester 2018, Biophytis pursued the SARA clinical program for the
drug candidate Sarconeos in sarcopenia. All 11 clinical centers of the SARA-OBS
clinical study (a study of observation and pre-recruitment without
administration) have been opened: 3 in the United States, 1 in Belgium, 3 in
France, 4 in Italy. As of June 30th, 162 patients were enrolled in the study.
At the same time, Biophytis continued the regulatory work to obtain the
authorisations and the opening of clinical centers for the phase 2b of SARA-INT
study, which allowed the opening of the first clinical center in Belgium in
May.

Also, the Company launched preparatory work for the MYODA program in Duchenne
Muscular Dystrophy, which resulted in the obtention of Orphan Drug status for
Sarconeos with the Food and Drug Agency (FDA) and European Medicines Agency
(EMA).

Finally, the research efforts have been maintained. The Company filed a new
patent, the 7th to date, concerning the research platform for MAS receptor
activator for muscle and metabolism pathologies. Four scientific works were
presented at the 8th International Conference on Frailty & Sarcopenia Research
in Miami. Finally, one poster was presented at the annual congress of the
Association for Research in Vision and Ophtalmology (ARVO) in Honolulu, Hawai,
in May. The presented results demonstrate the strong potential of Macuneos in
the treatment of Age-Related Macular Degeneration (AMD).

Interim financial results 2018

In EUR thousands H1 2018 H1 2017

Net Research and Development Costs (4,136) (2,912)
General and administrative expenses (1,542) (1,247)
Operating income (5,678) (4,159)
Financial income (12) (855)
Net Income (5,690) (5,014)

The operating income at end of June 2018 was (5,678) kEUR versus (4,159) kEUR
at end of June 2017. This change is mainly due to :

* An increase of 653 kEUR in third-party research and development expenses
versus the same period in 2017, mainly due to the combination of conducting
simultaneously the last part of the SARA-OBS study and the launch of the
SARA-INT study ;
* Increase in personnel expenses of 928 kEUR versus the same period in 2017,
mainly due to the increase of overall staff ;
The financial result of (12) kEUR at end of June 2018 versus (855) kEUR at end
of June 2017, significantly improved as in 2017 the company was bearing the
financial charges of convertible bonds which was no longer the case in 2018.

At end of June 2018, the company held two short-term deposit accounts of
respectively 7,000 kEUR and 3,000kEUR.

Post-closing events

On September 10th, the Company entered into a venture loan agreement with Kreos
Capital V (UK) LTD (" KREOS ") by signing a Bonds Issue Agreement for up to 10
MEUR, with issuance of 442 477 warrants attached to the Tranche A
(BSA2018-KREOS), and a pledge on part of the Company's goodwill in favour of
KREOS.

o The agreement allows for raising up to 10 M EUR by an issue of
non-convertible Bonds for a total nominal amount of up to 10 MEUR with a
par value of 1EUR per bond, divided into 4 tranches of 2,5 M EUR each. The
issue dates are established as at the contract signature date : the first
two tranches shall be issued by September 30th 2018, the third and fourth
tranches shall be issued in the 4th quarter of 2018 and first quarter of
2019, with the possibility to postpone one of the issues to the second
quarter of 2019. The nominal interest rate of each tranche is 10% per
annum. The tranches shall be repaid in accordance with a 36-months
amortisation schedule, following the nominal amount grace period, starting
from April 2019. Tranches A and B were issued on 10th September.

o Each warrant (BSA2018-KREOS) issued in favour of KREOS in the Tranche A
scope gives the right to subscribe to one new share of the Company. The
warrants are exercisable within a 7 years period starting from their
emission date, at an exercise price of 2,67 EUR.

o A pledge on part of the Company's goodwill has been granted on September
10th.

Perspective on the activity to come

The company will continue to advance its three clinical programs :

Development of Sarconeos in sarcopenia: Phase 2B clinical study, SARA-INT The
double-blind, placebo-controlled Phase 2b SARA-INT study will include
approximately 334 patients. 7 centres are already opened in the United States
and in Belgium, and the company is awaiting the authorizations from the French
and Italian regulatory agencies. More than 200 patients have already been
recruited in the SARA-OBS study, which includes 11 clinical centres in Europe
(Belgium, France and Italy) and in the United States. 60 have completed the
observational study and are ready to enter the interventional study. The
remaining patients will be recruited in 11 additional clinical centres. The
company forecasts to complete recruitment in S1 2019.

Development of Sarconeos in Duchenne Muscular Dystrophy: MYODA clinical
program
Sarconeos has already received the orphan drug status granted by the FDA and
the EMA (European Medicines Agency) in the Duchenne Muscular Dystrophy. This
status will allow Biophytis to benefit from numerous incentives for the
development of its drug candidate, including a marketing exclusivity of 10
years in the European Community and 7 years in the USA. The company has
requested the scientific advice from FDA and EMA regarding the clinical
program, and expects to obtain regulatory approvals for the MYODA-PK study of
safety and pharmacokinetics in patients in S1 2019.

Development of Macuneos in AMD: Phase 1/2a clinical study, MACA-PK
The company is currently conducting the industrial scale-up of the clinical
lots of the Macuneos drug candidate. It intends to request the scientific
advice from FDA and EMA in Q1 2019, and to obtain regulatory approvals for the
MACA-PK study of safety and pharmacokinetics in healthy volunteers in S1
2019.

About BIOPHYTIS
Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates
targeting diseases of aging. Using its technology and know-how, Biophytis has
begun clinical development of innovative therapeutics to restore the muscular
and visual functions in diseases with significant unmet medical needs.
Specifically, the company is advancing two lead products into mid-stage
clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and
Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).
The business model of BIOPHYTIS is to ensure the conduct of the project until
clinical activity in the patient is proven, then to license the technologies in
order to continue the development in partnership with a pharmaceutical
laboratory.
Based on the Sorbonne Université campus, Biophytis collaborates with expert
scientists from several Sorbonne Université institutes such as the Paris Seine
Biology Institute, the Institute of Myology, and the Vision Institute.

This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version
shall prevail.